{
    "clinical_study": {
        "@rank": "149819", 
        "arm_group": [
            {
                "arm_group_label": "SJP-0035 Ophthalmic Solution", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks."
            }, 
            {
                "arm_group_label": "- Vehicle of SJP-0035 Ophthalmic Solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in\n      promoting corneal epithelial wound healing in conditions associated with corneal epithelial\n      disorders."
        }, 
        "brief_title": "Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Corneal Epithelial Disorders", 
        "detailed_description": {
            "textblock": "There is currently no product approved for corneal epithelial wound healing. A Phase 1 Study\n      SJP-0035/1-01 was conducted in healthy volunteers to investigate the safety, tolerability,\n      and pharmacokinetic profile of SJP-0035 ophthalmic solution and to determine the appropriate\n      dose to be evaluated in patients with moderate to severe corneal epithelial disorders.\n\n      This Phase 2a study is being conducted to evaluate the safety and efficacy of SJP-0035\n      ophthalmic solution in patients to promote corneal epithelial wound healing in conditions\n      associated with corneal epithelial disorders."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female between the ages of 20 and 64 years, inclusive.\n\n          -  Has moderate to severe superficial punctate keratitis (SPK) and/or corneal  erosion\n             in 1 or both eyes.\n\n          -  Has symptoms caused by corneal epithelial disorders.\n\n          -  Has not obtained improvement from previous treatment for the SPK or corneal erosion\n             within the last 30 days.\n\n          -  Is a female of childbearing potential with a negative pregnancy test result at\n             Screening and baseline and agrees to use effective contraception throughout the study\n             or is a postmenopausal woman with a negative pregnancy test result at Screening and\n             baseline.\n\n        Exclusion Criteria:\n\n          -  Has any corneal stromal or endothelial abnormalities including an active bacterial or\n             viral ocular infection, bullous keratopathy, or chemical burns or any trauma to the\n             cornea.\n\n          -  Any active or chronic allergic, bacterial, or viral infection of ocular adnexa and\n             eye structures.\n\n          -  Had previous ocular/refractive surgery (including laser surgery) within the last 6\n             months.\n\n          -  Has used any ocular medication (except mydriatics, stain, and topical anesthesia used\n             for study assessments) within 14 days prior to the first dose of study drug, or who\n             are anticipated to require such medications during the study. Artificial tears may be\n             used up to 72 hours prior to the first dose.\n\n          -  Is unable to discontinue Restasis. A 28-day washout period prior to the first dose of\n             study drug is required.\n\n          -  Is a contact lens wearer and cannot discontinue use for the duration of the study.\n\n          -  Alcohol or drug abuse within the past 6 months.\n\n          -  Positive hepatitis B surface antigen, hepatitis C virus antibody, or human\n             immunodeficiency virus test at Screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104388", 
            "org_study_id": "SJP-0035/2-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "SJP-0035 Ophthalmic Solution", 
                "intervention_name": "SJP-0035 Ophthalmic Solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "- Vehicle of SJP-0035 Ophthalmic Solution", 
                "intervention_name": "Vehicle for SJP-0035 Ophthalmic Solution", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Christian Hester, MD", 
                    "phone": "501-224-5658"
                }, 
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72205"
                    }, 
                    "name": "Senju Investigational Site"
                }, 
                "investigator": {
                    "last_name": "Christian Hester, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kristie Bacon", 
                    "phone": "859-331-9000", 
                    "phone_ext": "4120"
                }, 
                "facility": {
                    "address": {
                        "city": "Edgewood", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "41017"
                    }, 
                    "name": "Senju Investigational site"
                }, 
                "investigator": {
                    "last_name": "Edward Holland, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cynthia Wood", 
                    "phone": "336-802-2255"
                }, 
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27262"
                    }, 
                    "name": "Senju Investigational Site"
                }, 
                "investigator": {
                    "last_name": "Michael Tepedino, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kayla Riley", 
                    "phone": "605-719-3153"
                }, 
                "facility": {
                    "address": {
                        "city": "Rapid City", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57701"
                    }, 
                    "name": "Senju Investigational Site"
                }, 
                "investigator": {
                    "last_name": "Stephen Khachikian, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders", 
        "overall_contact": {
            "email": "angela.donahue@ppdi.com", 
            "last_name": "Angela Donahue, Sr Director, Proj Management", 
            "phone": "919-732-8959"
        }, 
        "overall_contact_backup": {
            "email": "ashley.simmons@ppdi.com", 
            "last_name": "Ashley Simmons, Fellow, Proj Management", 
            "phone": "919-456-6408"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A patient will be considered a success for clearing of corneal fluorescein staining if their fluorescein staining has dissappeared.", 
            "measure": "Clearing of corneal fluorescein staining at week 4", 
            "safety_issue": "No", 
            "time_frame": "measured at Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104388"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "An Adverse Event is defined as any untoward medical occurrence in a patient enrolled into the study regardless of its causal relationship to study drug.", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety.", 
                "safety_issue": "Yes", 
                "time_frame": "baseline up to week 18"
            }, 
            {
                "description": "100-point assessments are performed for the symptom of blurred vision,  photophobia and eye irritation.", 
                "measure": "Changes of subjective symptoms: blurrred vision, photophobia and eye irritation", 
                "safety_issue": "No", 
                "time_frame": "screening up to  week 18"
            }, 
            {
                "description": "These changes are measured at every study visit using standard ophthalmology procedures.", 
                "measure": "Changes of subjective signs: tear stability, conjunctival epithelia, and surface curvature of cornea", 
                "safety_issue": "No", 
                "time_frame": "screening up to week 18"
            }
        ], 
        "source": "Senju Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Senju Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}